Cardio Diagnostics Holdings (NASDAQ: CDIO) is applying artificial intelligence, epigenetics and genetics to a problem that traditional diagnostic tools have never fully solved: detecting coronary heart disease, including forms that standard methods routinely miss, from a simple blood draw. The Chicago-based precision cardiovascular medicine company is targeting a cardiovascular disease market that, according to the American Heart Association (AHA), accounted for more than 940,000 deaths in the United States in 2022, maintaining its position as the nation’s number one killer.
For cardiovascular conditions, annual health care costs are forecasted to increase from $393 billion in 2020 to $1.4 trillion by 2050, almost quadrupling in size, according to the AHA. Into that persistent and costly healthcare burden steps Cardio Diagnostics, which aims to detect coronary heart disease earlier and with high sensitivity.
What makes Cardio Diagnostics’ approach distinct, and what gives the company a defensible clinical position, is its ability to detect coronary heart disease earlier and with high sensitivity. The company’s recent commercial and regulatory milestones give additional shape to the investment thesis.
The scale of the problem that Cardio Diagnostics is working to address is difficult to overstate. According to the AHA, cardiovascular disease remains the leading cause of death across men, women, and most racial and ethnic groups in the nation, with one person dying every 34 seconds from the condition. Despite advances in medicine, the problem is getting worse, not better.
For leaders in business and technology, the implications are significant. Heart disease is not only a health crisis but also an economic one. The rising healthcare costs associated with cardiovascular disease place a burden on employers, insurers, and the broader economy. Early detection could reduce hospitalizations, lower treatment costs, and improve patient outcomes, potentially saving billions of dollars annually.
Cardio Diagnostics’ use of epigenetics—the study of changes in gene expression—combined with artificial intelligence, represents a shift toward personalized, data-driven medicine. This approach could set a new standard for cardiovascular diagnostics, offering a non-invasive, accurate alternative to traditional methods that often miss early-stage disease.
The company’s newsroom at https://ibn.fm/CDIO provides the latest updates and information on its progress. Investors should note that forward-looking statements in this article involve risks and uncertainties, as detailed in the company’s SEC filings. More information on disclaimers is available at http://IBN.fm/Disclaimer.
